Welcome to our dedicated page for Cutera news (Ticker: CUTR), a resource for investors and traders seeking the latest updates and insights on Cutera stock.
Cutera Inc (CUTR) is a global leader in medical aesthetics, pioneering advanced laser systems for skin treatments and body contouring. This page serves as the definitive source for official company announcements, financial disclosures, and technology developments.
Access real-time updates on earnings reports, FDA clearances, product launches, and strategic partnerships. Investors and practitioners alike rely on this centralized hub for tracking innovations in energy-based aesthetic devices and corporate milestones.
Our curated news feed includes clinical study results, regulatory updates, and market expansion announcements. Stay informed about CUTR's advancements in ND:YAG technology and international service network developments through verified primary sources.
Bookmark this page for streamlined access to CUTR's evolving position in the $6B medical aesthetics sector. Check regularly for critical updates affecting treatment protocols, device safety profiles, and corporate financial health.
Cutera (CUTR) has announced its voluntary decision to delist its common stock from the Nasdaq Global Select Market. The company plans to file a Form 25 with the SEC around March 20, 2025, with the delisting expected to become effective near March 30, 2025.
Following the delisting, Cutera intends to file a Form 15 to indefinitely suspend its SEC reporting obligations, including Annual Reports (10-K), Quarterly Reports (10-Q), and Current Reports (8-K). The company has not arranged for alternative listing or registration on another national securities exchange, and there is no guarantee of a future public trading market for its common stock.
Cutera (CUTR) has announced a major financial restructuring plan through a pre-packaged Chapter 11 filing, aimed at strengthening its balance sheet. The plan, supported by 74% of the company's noteholders, will reduce debt by nearly $400 million (over 90%) and secure $65 million in new funding from existing lenders.
The company expects to complete the court-supervised process within 60 days, during which it will continue normal operations globally. Following the restructuring, Cutera will transition to a private company, backed by a consortium of investment firms. The restructuring only affects U.S. entities, with international operations remaining unchanged.
The company has filed for vendor payment approval to maintain normal business relationships and continue providing aesthetic and dermatology solutions without disruption.
Cutera has announced a partnership with the Adaptive Training Foundation (ATF) to provide truFlex muscle stimulation treatments to adaptive athletes. Supported by Dr. Edward Alvarez, the initiative aims to enhance the strength, muscle tone, and endurance of ATF participants during a nine-week specialized training course called ReDefine. The course includes physical and mental training to help participants redefine their sense of self. A survey study highlighted improvements in areas like the abdomen, glutes, and thighs. David Vobora, ATF Founder, praised the technology for increasing muscle function and body empowerment. Cutera plans to donate the truFlex device to ATF at the end of the year. For more information, visit yourtrubody.com and adaptivetrainingfoundation.org.
Cutera (CUTR) reported Q3 2024 financial results with consolidated revenue of $32.5 million, representing a 30% decrease compared to Q3 2023. The company maintained cash and equivalents of $59.0 million. AviClear showed 16% growth year-over-year in international markets, while global core capital grew 7% sequentially. Gross profit was $1.8 million (6% of revenue), down from $6.5 million (14%) in Q3 2023. Operating loss was $36.2 million. Management reaffirmed full-year revenue guidance of $140-145 million and year-end 2024 cash guidance of approximately $40 million.
Cutera, Inc. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, has announced that it will report its financial results for the third quarter ended September 30, 2024, after the market closes on Thursday, November 7, 2024. The company's management will host a conference call to discuss these results at 1:30 p.m. PT (4:30 p.m. ET) on the same day.
Participants can register for the conference call through a provided link, which will offer dial-in details and a unique PIN upon registration. Alternatively, participants can dial Canada/USA Toll Free: 1-844-763-8274 or +1-647-484-8814. The call will also be webcast and accessible from the Investor Relations section of Cutera's website. A webcast replay will be available approximately one hour after the call ends.
Cutera Inc. (Nasdaq: CUTR) reported Q2 2024 financial results with consolidated revenue of $34.4 million, a 44% decrease compared to Q2 2023. Key highlights include:
- AviClear growth of 41% vs prior year period
- Service growth of 7% vs prior year period
- Cash, cash equivalents, and restricted cash of $84.3 million
- Completion of Q4 2023 corporate restructuring program
- Additional $10 million cost reduction opportunity identified
The company revised its full-year revenue guidance to $140-$145 million and updated cash guidance to approximately $40 million by year-end. Steve Kreider was promoted to SVP, North America, to lead the combined North American commercial organization.
Cutera (Nasdaq: CUTR) has announced an exclusive distribution agreement with L'Oréal Japan Co. to promote, market, sell, and distribute select SkinCeuticals products to medical and physician-led clinics in Japan. The partnership, initially spanning three years with renewal options, aims to expand access to high-quality skincare solutions in the Japanese aesthetics market.
Key points:
- L'Oréal Japan Co. will provide marketing and advertising support
- Cutera KK strengthens its position in the Japanese aesthetics market
- SkinCeuticals products will be introduced in Q4 2023
- Financial impact expected to be immaterial in 2024
Cutera (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, has announced that it will release its second quarter 2024 financial results on August 8, 2024, after market close. The company will host a conference call at 1:30 p.m. PT (4:30 p.m. ET) on the same day to discuss the results. Participants can register for the call using a provided link, which will bypass the operator queue. Alternatively, they can dial in using toll-free numbers. The call will also be webcast from Cutera's Investor Relations website. A replay will be available approximately one hour after the call ends.
Cutera has released new survey data during June’s Acne Awareness Month, highlighting the impact of acne on individuals and the growing interest in modern treatments. The survey, conducted in partnership with EvolveMKD and FocalData, involved 500 U.S. acne sufferers. Key findings include that 90% of respondents experience daily insecurities, 43% worry about never achieving clear skin, and 60% find the struggle to treat acne more distressing than acne itself. The survey also indicates a significant interest in AviClear, Cutera's FDA-cleared energy-based acne treatment device. Half of those aware of AviClear express interest in trying it, and 81% want to learn more about in-office treatments, with lasers being the most considered option. Cutera’s CEO, Taylor Harris, emphasizes the company's commitment to transforming lives through innovative technologies. Additional activities for Acne Awareness Month include an AviClear investor webinar on June 20, 2024, and a sweepstakes offering a $500 prize for sharing acne-related experiences.
Cutera (Nasdaq: CUTR) has appointed Jeryl 'Jeri' Hilleman to its Board of Directors, effective July 12, 2024. Hilleman brings over 30 years of experience in the healthcare industry, with a strong background in financial leadership, strategic planning, and corporate governance. She has served as CFO for multiple public healthcare companies, including Intersect ENT, Ocera Therapeutics, and Amyris. CEO Taylor Harris highlighted her expertise as critical for Cutera's growth and innovation, particularly with products like AviClear. Hilleman has also held significant governance roles, such as Chair of the Board at Omada Health and Audit Committee Chair at NovoCure, Minerva Neurosciences, and others.
